CC-90011 for Prostate Cancer

Phase-Based Progress Estimates
Memorial Sloan Kettering Cancer Center, New York, NYProstate CancerCC-90011 - Drug
What conditions do you have?

Study Summary

This trial will test whether CC-90011 can make tumors sensitive to anti-hormonal therapy again by inducing androgen receptor expression.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Through study completion, Up to 1.5 years

Day 28
Androgen Receptor
Day 90
Safety and tolerability assessed by Adverse events (AEs)
Year 5
Safety and tolerability assessed by dose-limiting toxicities (DLTs)
Year 3
Assessment of anti-tumor activity

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

CC-90011 in combination with Abiraterone and Prednisone
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: CC-90011 · No Placebo Group · Phase 1

CC-90011 in combination with Abiraterone and PrednisoneExperimental Group · 3 Interventions: CC-90011, Abiraterone, Prednisone · Intervention Types: Drug, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, up to 1.5 years

Who is running the clinical trial?

CelgeneLead Sponsor
625 Previous Clinical Trials
123,109 Total Patients Enrolled
5 Trials studying Prostate Cancer
1,270 Patients Enrolled for Prostate Cancer
Zariana Nikolova, MD, PhDStudy DirectorCelgene
5 Previous Clinical Trials
519 Total Patients Enrolled
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,414 Previous Clinical Trials
3,310,571 Total Patients Enrolled
14 Trials studying Prostate Cancer
4,383 Patients Enrolled for Prostate Cancer

Eligibility Criteria

Age 18+ · Male Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Has CC-90011 been the focus of prior scientific exploration?

"Presently, there are 366 ongoing trials involving CC-90011 with a hundred of those in the final phase. While most experiments concerning this drug are based out of Duarte, California, over 17 thousand sites worldwide have started research into this medication." - Anonymous Online Contributor

Unverified Answer

What is the cutoff for participants being allowed to join this research endeavor?

"Affirmative. According to, this medical research is still in the recruitment process. It was initially posted on July 28th 2021 and recently updated on July 21st 2022. The study requires 10 patients from a single site." - Anonymous Online Contributor

Unverified Answer

To what medical conditions is CC-90011 typically prescribed?

"CC-90011 is a therapeutic agent used to treat thyroiditis and other maladies including ulcerative colitis, cancerous growths, and varicella-zoster virus acute retinal necrosis." - Anonymous Online Contributor

Unverified Answer

To what extent do the risks of CC-90011 outweigh its potential advantages?

"CC-90011 is a relatively new medication, so its safety score was assessed at 1. This reflects the fact that there are only limited clinical data supporting both efficacy and safety in this Phase 1 trial." - Anonymous Online Contributor

Unverified Answer

Is there any vacancy for participants in this trial?

"According to the records, this study has been recruiting since its inception on July 28th 2021 and is still actively enrolling patients as of the latest update dated July 21st 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.